REVA to Hold Briefing Call on Q2 2014 Financial Results

        Print
| Source: REVA Medical, Inc.

SAN DIEGO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a conference call to discuss the Company's financial results through June 30, 2014 and its business outlook. Robert Stockman, the Company's Chairman and Chief Executive Officer, will host the call and along with Robert Schultz, Chief Operating Officer, and Katrina Thompson, Chief Financial Officer, will provide details on operations and answer questions.

The call is scheduled for 4:00 p.m. US PDT on Tuesday, August 12, 2014 (which is 9:00 a.m. AEST on Wednesday, 13 August 2014) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing (02) 8223 9773. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly.

If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit "Events & Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A replay of the audiocast will be available on our website after the call.

About REVA

REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stent products, also called "scaffolds." Utilizing its stent designs and proprietary polymers, the Company designs its scaffolds to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The Company has conducted clinical studies of its scaffold technologies and its next generation scaffold FantomTM is in the development and testing phase. A total of 112 patients were enrolled in its most recent clinical trial in Australia, Brazil, Europe, and New Zealand; they will be followed for a total of five years, with primary data to be obtained at nine and 12 months. First human implants of Fantom are planned for late 2014 at multiple centers in Brazil and Europe. REVA will require successful clinical results and regulatory approval before it can commercialize Fantom or any of its other products.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Cheryl Liberatore
Director, Investor Relations
+1 858-966-3045

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 2 9229 2700

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722
Annabel Murphy
+61 2 9237 2800